Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Greenway Greenhouse Cannabis's 5-Year Yield-on-Cost % or its related term are showing as below:
GWAYF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.325 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Greenway Greenhouse Cannabis 5-Year Yield-on-Cost % Related Terms
GWAYF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Greenway Greenhouse Cannabis's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenway Greenhouse Cannabis 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Greenway Greenhouse Cannabis's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Greenway Greenhouse Cannabis's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Greenway Greenhouse Cannabis (GWAYF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Greenway Greenhouse Cannabis and its competitors. According to the industry distribution chart, Greenway Greenhouse Cannabis ranks #999999 out of 514 companies in the Drug Manufacturers industry.
Is Greenway Greenhouse Cannabis' 5-Year Yield-on-Cost % too high?
Greenway Greenhouse Cannabis' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Greenway Greenhouse Cannabis ranks #999999 out of 514 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Greenway Greenhouse Cannabis has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Greenway Greenhouse Cannabis' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Greenway Greenhouse Cannabis ranks #999999 out of 514 companies for 5-Year Yield-on-Cost %. This places Greenway Greenhouse Cannabis in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.33, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Greenway Greenhouse Cannabis and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenway Greenhouse Cannabis's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenway Greenhouse Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Greenway Greenhouse Cannabis (GWAYF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.08 — trading 73.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Greenway Greenhouse Cannabis' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Greenway Greenhouse Cannabis (GWAYF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Greenway Greenhouse Cannabis (GWAYF) Overvalued in 2026?
Based on GuruFocus' analysis, Greenway Greenhouse Cannabis stock appears to be undervalued.
The current stock price of $0.08 is trading 73.5% below its estimated GF Value™ of $0.29.
GuruFocus considers Greenway Greenhouse Cannabis to be Possible Value Trap.
Key valuation signals for GWAYF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.29 vs. price of $0.08 (73.5% below fair value)
No single metric tells the full story. See the GWAYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Greenway Greenhouse Cannabis Corp is licensed to cultivate, process and sell to ensures harvests always consist of the highest quality cannabis strains with resinous flowers, trichomes, and rich cannabinoid profiles. The Company's nursery facility is located in Kingsville, Ontario, and its flowering and processing facility is located in Leamington, Ontario. The business model is to supply bulk packaged, high quality cannabis to the Canadian, cannabis industry at prices that ultimately provide a value proposition to the consumers. Greenway has three divisions with various locations; Greenway Nursery, Greenway Cultivation and future plans for Greenway Farmgate Retail Store.
26GF Score
Get the complete analysis for GWAYF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GWAYF has been successfully added to your 
